Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 3/20 | 0.37 |
| ▸ | HRH1 | P35367 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4674542 | 0.86 | — | — | |
| SCHEMBL3896587 | 0.86 | — | — | |
| SCHEMBL2332619 | 0.78 | MAOB (0.33) | JAK2JAK1TYK2JAK3ALDH1A1 | |
| SCHEMBL4375132 | 0.77 | MAOB (0.34) | HRH3JAK2JAK1TYK2JAK3 | |
| SCHEMBL3442988 | 0.77 | ALDH1A1 (0.62) | GPR119KCNA3HRH2HRH1HRH3 | |
| SCHEMBL665736 | 0.76 | ACHE (0.43) | KCNA3HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL1414426 | 0.76 | MAOB (0.45) | — | |
| SCHEMBL22691891 | 0.76 | MAOB (0.36) | JAK2JAK1TYK2JAK3ALDH1A1 | |
| SCHEMBL665735 | 0.76 | ALDH1A1 (0.33) | JAK2JAK1TYK2JAK3ALDH1A1 | |
| SCHEMBL8903856 | 0.76 | GPR119 (0.39) | GPR119KCNA3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8333340-A | — | — | None | — | — | JP | disclosed |
| EP-4554574-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119698278-A | Small molecule modulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024015889-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-18 | — | — | WO | disclosed |
| US-7557215-B2 | Anthraquinone compounds as anti cancer compounds | SOMANTA LIMITED (GB) | 2009-07-07 | — | — | US | disclosed |
| CN-101395150-A | Phenethanolamine derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | CN | disclosed |
| EP-1701939-B1 | ANTHRAQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | SOMANTA LTD (GB) | 2009-02-25 | — | — | EP | disclosed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-2013197-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008062252-A1 | N-OXIDES OF CYTOTOXIC ANTHRAQUINONES AS HYPOXIA-TARGETING PRODRUGS IN CANCER TREATMENT | ACCESS PHARMACEUTICALS, INC (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080027107-A1 | Antharquinone Compounds as Anti Cancer Compounds | SOMANTA LIMITED (GB) | 2008-01-31 | — | — | US | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
| EP-1701939-A1 | ANTHRAQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | Somanta Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005061453-A1 | ANTHARQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS | SOMANTA LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2002096361-A2 | 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| JP-H08333340-A | PRODUCTION OF AMINOETHYLPIPERIDINE DERIVATIVE | FUJIREBIO INC | 1996-12-17 | — | — | JP | disclosed |
| US-4261990-A | N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics | CIBA-GEIGY CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027107-A1 | Antharquinone Compounds as Anti Cancer Compounds | TOP2A, TOP2B, RECQL | GPR119 1838/4885KCNA3 2504/4885HRH2 42/4885 |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | GPR119 310/4885KCNA3 417/4885HRH2 12/4885 |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | GPR119 743/4885KCNA3 3265/4885HRH2 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.